Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Borcherding

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Clinical Chemistry|August 5, 2021
Commentary on a Case of Unexpected HyperglycemiaNicholas Borcherding, Ann M Gronowski
Nature|November 8, 2023
The power and potential of mitochondria transferNicholas Borcherding, Jonathan R Brestoff
Molecular & Cellular Oncology|June 17, 2016
Paracrine WNT5A signaling in healthy and neoplastic mammary tissueDavid Kusner, Nicholas Borcherding, Weizhou Zhang
Advances in Experimental Medicine and Biology|February 16, 2020
IL-1 Signaling in Tumor MicroenvironmentWeizhou Zhang, Nicholas Borcherding, Ryan Kolb
Cancer Management and Research|December 22, 2018
The clinical promise of immunotherapy in triple-negative breast cancerPraveen Vikas, Nicholas Borcherding, Weizhou Zhang
Drug Design, Development and Therapy|November 26, 2020
Repurposing Anti-Cancer Drugs for COVID-19 TreatmentNicholas Borcherding, Yogesh Jethava, Praveen Vikas
Advances in Experimental Medicine and Biology|February 1, 2021
Understanding and Targeting Human Cancer Regulatory T Cells to Improve TherapyH Ryan Kolb, Nicholas Borcherding, Weizhou Zhang
F1000Research|August 18, 2020
scRepertoire: An R-based toolkit for single-cell immune receptor analysisNicholas Borcherding, Nicholas L Bormann, Gloria Kraus
Frontiers in Oncology|May 28, 2020
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid TumorsPraveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, et al.
Plos One|April 28, 2023
IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changesMichael P Crawford, Nicholas Borcherding, Nitin J Karandikar
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Clinical Chemistry|August 5, 2021
Commentary on a Case of Unexpected HyperglycemiaNicholas Borcherding, Ann M Gronowski
Nature|November 8, 2023
The power and potential of mitochondria transferNicholas Borcherding, Jonathan R Brestoff
Molecular & Cellular Oncology|June 17, 2016
Paracrine WNT5A signaling in healthy and neoplastic mammary tissueDavid Kusner, Nicholas Borcherding, Weizhou Zhang
Advances in Experimental Medicine and Biology|February 16, 2020
IL-1 Signaling in Tumor MicroenvironmentWeizhou Zhang, Nicholas Borcherding, Ryan Kolb
Cancer Management and Research|December 22, 2018
The clinical promise of immunotherapy in triple-negative breast cancerPraveen Vikas, Nicholas Borcherding, Weizhou Zhang
Drug Design, Development and Therapy|November 26, 2020
Repurposing Anti-Cancer Drugs for COVID-19 TreatmentNicholas Borcherding, Yogesh Jethava, Praveen Vikas
Advances in Experimental Medicine and Biology|February 1, 2021
Understanding and Targeting Human Cancer Regulatory T Cells to Improve TherapyH Ryan Kolb, Nicholas Borcherding, Weizhou Zhang
F1000Research|August 18, 2020
scRepertoire: An R-based toolkit for single-cell immune receptor analysisNicholas Borcherding, Nicholas L Bormann, Gloria Kraus
Frontiers in Oncology|May 28, 2020
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid TumorsPraveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, et al.
Plos One|April 28, 2023
IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changesMichael P Crawford, Nicholas Borcherding, Nitin J Karandikar
Pageof 9